Treatment for Active Herpes Simplex Outbreak
For an active herpes simplex outbreak, initiate oral antiviral therapy immediately—the most practical regimens are acyclovir 400 mg three times daily for 5 days, valacyclovir 500 mg twice daily for 5 days, or famciclovir 125 mg twice daily for 5 days, with treatment ideally started within 1 day of lesion onset or during prodrome for maximum benefit. 1
Treatment Approach Based on Clinical Scenario
First Clinical Episode (Primary Infection)
- Acyclovir 200 mg orally 5 times daily for 7-10 days until clinical resolution 2
- This longer duration is critical because primary infections are typically more severe with systemic symptoms
- First episodes may present with malaise, fever, and localized adenopathy requiring extended therapy 3
Recurrent Episodes (Most Common Scenario)
The 1998 CDC guidelines 1 provide the most recent and comprehensive treatment options:
Recommended episodic regimens (choose one):
- Acyclovir 400 mg orally three times daily for 5 days, OR
- Acyclovir 200 mg orally five times daily for 5 days, OR
- Acyclovir 800 mg orally twice daily for 5 days, OR
- Famciclovir 125 mg orally twice daily for 5 days, OR
- Valacyclovir 500 mg orally twice daily for 5 days
Critical timing consideration: Treatment must begin during prodrome or within 1 day of lesion onset to achieve meaningful benefit 1. Starting treatment after this window provides minimal clinical improvement in immunocompetent patients 2.
Severe Disease Requiring Hospitalization
- Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days until clinical resolution 1
- Indications include disseminated infection, encephalitis, pneumonitis, hepatitis, or meningitis
- For HSV-2 meningitis specifically: acyclovir 10 mg/kg IV every 8 hours until fever/headache resolve, then valacyclovir 1 g three times daily to complete 14 days 4
Special Populations
Immunocompromised patients:
- Require more aggressive therapy with prolonged treatment courses 2
- Higher risk of acyclovir-resistant strains—if treatment failure occurs, consider foscarnet or cidofovir 4, 5
- Emerging option: pritelivir (helicase-primase inhibitor) for acyclovir-resistant cases in open-label trials 4
HIV-infected patients:
- Monitor closely as healing is slower and treatment failures more common 1
- May require longer courses than standard recommendations
Key Clinical Pearls
Valacyclovir and famciclovir advantages:
- Comparable efficacy to acyclovir but with improved dosing convenience 1
- Better patient adherence due to less frequent dosing 6
- Valacyclovir achieves higher bioavailability as the prodrug of acyclovir 6
Topical therapy:
- Substantially less effective than oral medications and should be avoided 2
- Exception: 1% penciclovir cream shows superiority over topical acyclovir for facial HSV if topical route preferred 7
Patient counseling during outbreak:
- Abstain from sexual activity while lesions present 2
- Transmission can occur during asymptomatic periods, but risk highest with active lesions 1
- Condom use should be encouraged for all sexual exposures 2
Common Pitfalls to Avoid
Delayed treatment initiation: The narrow therapeutic window (prodrome to 1 day post-lesion onset) is frequently missed, rendering treatment less effective 1
Prescribing topical acyclovir: This route has equivocal efficacy and should not be used 2
Inadequate duration for first episodes: Primary infections require 7-10 days, not the 5-day course used for recurrences 2
Missing severe disease indicators: Hospitalize patients with systemic complications—oral therapy is insufficient 1
Suppressive Therapy Consideration
While not treatment for an active outbreak, patients with frequent recurrences (≥6 per year) should be offered daily suppressive therapy after the acute episode resolves: